Reveleer vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
AI-powered risk adjustment, quality management, and HEDIS analytics for health plans and ACOs; raised $60M+. Glendale CA;
About
Reveleer is a health IT company that provides AI-powered solutions for risk adjustment, quality management, and care gap closure to health plans, ACOs, and provider organizations. Founded in 2014 and headquartered in Glendale, California, Reveleer has raised more than $60 million in growth capital. Its platform combines intelligent document ingestion, natural language processing, and workflow automation to help payers accurately capture risk and close quality gaps at scale, supporting programs like Medicare Advantage, Medicaid Managed Care, and ACA Marketplace.\n\nThe company's core capabilities include automated medical record retrieval, AI-assisted HCC coding review, HEDIS measure tracking, and clinical analytics that surface actionable insights across member populations. Reveleer's platform is designed to serve the full risk adjustment lifecycle from retrospective chart review through prospective care coordination, enabling health plans to improve risk accuracy while simultaneously identifying members who need targeted outreach for quality improvement.\n\nReveleer competes in a market increasingly defined by the financial importance of accurate risk scoring in value-based care contracts. The company has expanded its technology to include an integrated analytics layer that connects risk adjustment and quality data, helping health plans understand the intersection between clinical gaps and revenue impact. Its cloud-native architecture and configurable workflow engine make it adaptable to the specific program requirements of national and regional health plans.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.